HC Wainwright Issues Pessimistic Estimate for OLMA Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - HC Wainwright reduced their Q2 2025 earnings per share estimates for Olema Pharmaceuticals in a note issued to investors on Monday, June 2nd. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.70) per share for the quarter, down from their previous estimate of ($0.37). HC Wainwright currently has a "Buy" rating and a $30.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals' Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.92) EPS and FY2026 earnings at ($3.86) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13.

A number of other research analysts have also issued reports on OLMA. Oppenheimer decreased their target price on shares of Olema Pharmaceuticals from $25.00 to $22.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th. JPMorgan Chase & Co. reduced their price target on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Friday, March 28th. Finally, The Goldman Sachs Group reduced their price target on Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th.

Olema Pharmaceuticals Stock Performance

Shares of OLMA stock traded up $0.25 on Wednesday, hitting $4.46. The company's stock had a trading volume of 995,785 shares, compared to its average volume of 821,109. The stock's 50 day moving average is $4.49 and its 200-day moving average is $5.45. Olema Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $16.62. The company has a market capitalization of $305.16 million, a PE ratio of -2.04 and a beta of 1.99.

Institutional Trading of Olema Pharmaceuticals

Large investors have recently made changes to their positions in the company. Jane Street Group LLC boosted its holdings in shares of Olema Pharmaceuticals by 216.8% in the 1st quarter. Jane Street Group LLC now owns 138,552 shares of the company's stock valued at $521,000 after purchasing an additional 94,815 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of Olema Pharmaceuticals by 8.9% in the 1st quarter. Woodline Partners LP now owns 1,477,907 shares of the company's stock valued at $5,557,000 after purchasing an additional 120,428 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Olema Pharmaceuticals by 93.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company's stock valued at $2,787,000 after purchasing an additional 358,412 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Olema Pharmaceuticals in the first quarter valued at about $172,000. Finally, MPM Bioimpact LLC boosted its stake in Olema Pharmaceuticals by 0.6% in the first quarter. MPM Bioimpact LLC now owns 2,930,446 shares of the company's stock valued at $11,018,000 after buying an additional 17,896 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.